 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
In large-scale construction and civil works, outdated or damaged pipelines can bring operations to a halt. At Revolution Pipe Relining, we understand that time is money—especially for remedial build...
Daily Bulletin
TP’s Business Insights report into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new light on how evolving channel preferences are resh...
Daily Bulletin
The air at the executive level is different. The stakes are higher, the competition more intense, and the path to your next leadership role requires a nuanced and strategic approach. Unlike more jun...
Daily Bulletin
